Abstract
Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by a progressive pulmonary vasculopathy with ensuing right heart failure if left untreated. In the 1980’s, prior to the current treatment era, idiopathic pulmonary arterial hypertension (IPAH) carried a poor prognosis with a 10 month median survival for children after diagnosis. However, in 1995 continuous intravenous epoprostenol was approved for the treatment of severe PAH, improving hemodynamics, quality of life, exercise capacity, functional class and survival. In the past decade there have been further advances in the treatment of PAH; however, there is still no cure. While much of the groundbreaking clinical research has been performed in adults, children have also seen the benefits of PAH novel therapies. The target population among pediatric patients is expanding with the recent recognition of pulmonary hypertension as a risk factor for sickle cell disease patients. With rapid advances, navigating the literature becomes challenging. A comprehensive review of the most recent literature over the past year on available and emerging novel therapies as well as an approach to target pediatric populations provides insights into the management of pediatric PAH patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
D’Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343–349.
Rich S, Kaufmann E, Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension [see comments]. N Engl J Med 1992; 327: 76–81.
Higenbottam T, Wheeldon P, Wells, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984; 1: 1046–1047.
Barst, RJ, Rubin LJ, McGoon MD et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121: 409–415.
Barst RJ, Maislin G, and Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197–1208.
Rubin, LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336(2): 111–117.
Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296–302.
Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. Outcomes in Children with Idiopathic Pulmonary Arterial Hypertension. Circulation 2004; 110: 660–665.
Barst RJ, Simonneau G, Rich S et al. For the Uniprost PAH Study Group. Efficacy and safety of chronic subcutaneous infusion of UT-15 (Uniprost) in pulmonary arterial hypertension (PAH). Circulation 2000; 102: 100–101.
Tapson VF, Gomberg-Maitland M, McLaughlin VV et al. Safety and Efficacy of IV treprostinil for pulmonary arterial hypertension: A prospective, multicenter open-label, 12-week trial. Chest 2006; 129: 683–688.
Ivy DD, Claussen L, Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol 2007; 99: 696–698.
Olschewski H, Simonneau G, Galie N et al. Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. NEJM 2002; 347: 322–329.
Hallioglu O, Dilber E, Celiker A. Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. Am J Cardiol 2003; 92: 1007–1009.
Limsuwan A, Wanitkul S, Khosithset A et al. Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease. Int J Cardiol 2007; 129: 333–339.
Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411–415.
Galie N, Grigioni F, Bacchi-Reggiani L et al. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension. Eur J Clin Invest 1996; 26: 273.
Yamane K. Endothelin and collagen vascular disease: a review with special reference to Raynaud’s phenomenon and systemic sclerosis. Intern Med 1994; 33: 579–582.
Giaid A, Yanagisa WA M, Langleben D et al. Expression of endothelin -1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732–1739.
Allen SW, Chatfield BA, Koppenhafer SA et al. Circulating immunoreactive endothelin-1 in children with pulmonary hypertension. Association with acute hypoxic pulmonary vasoreactivity. Am Rev Respir Dis 1993; 148: 519–522.
Rosenzweig EB, Ivy DD, Widlitz A et al. Effects of Longterm Bosentan in Children with Pulmonary Arterial Hypertension. JACC 2005; 46: 697–704.
Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart 2006; 92: 664–670.
van Loon RL, Hoendermis ES, Duffels MG et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-topulmonary shunt: doesthe beneficial effect persist? Am Heart J 2007; 154: 776–782.
Kageyama K, Hashimoto S, Nakajima Y et al. The change of plasma endothelin-1 levels before and after surgery with or without Down syndrome. Paediatr Anaesth 2007; 17: 1071–1077.
Galie N, Badesch D, Oudiz R et al. Ambrisentan therapy for pulmonary arterial hypertension. JACC 2005; 46: 529–535.
Hanson KA, Ziegler JW, Rybalkin SD et al. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am J Physiol 1998; 275: L931–L941.
Galie N, Ghofrani H, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148–2157.
Raja SG, Danton MD, MacArthur KJ, Pollock JC. Effects of escalating doses of sildenafil on hemodynamics and gas exchange in children with pulmonary hypertension and congenital cardiac defects. J Cardiothorac Vasc Anesth 2007; 21: 203–207.
Noori S, Friedlich P, Wong P et al. Cardiovascular effects of sildenafil in neonates and infants with congenital diaphragmatic hernia and pulmonary hypertension. Neonatology 2007; 91: 92–100. Epub 2006 Nov 20.
Nagendran J, Archer SL, Soliman D et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007; 116: 238–248.
Gladwin MT, Sachdev V, Jison ML et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350: 886–895.
Suell MN, Bezold LI, Okcu MF et al. Increased pulmonary artery pressures among adolescents with sickle cell disease. J Pediatr Hematol Oncol 2005; 27: 654–658.
Nelson SC, Adade BB, McDonough EA et al. High prevalence of pulmonary hypertension in children with sickle cell disease. J Pediatr Hemato/Oncolo 2007; 29: 334–337.
Dessap AM, Leon R, Habibi A et al. Pulmonary Hypertension and Cor Pulmonale during Severe Acute Chest Syndrome in Sickle Cell Disease. Am J Respir Crit Care Med 2008; 177: 646–653.
Onyekwere OC, Campbell A, Teshome M et al. Pulmonary Hypertension in Children and Adolescents with Sickle Cell Disease. Pediatr Cardiol 2008; 29: 309–312.
Liem RI, Young LT, Thompson AA. Tricuspid regurgitant jet velocity is associated with hemolysis in children and young adults with sickle cell disease evaluated for pulmonary hypertension. Haematologica 2007; 92: 1549–1552.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rosenzweig, E.B., Barst, R.J. Pulmonary arterial hypertension in children: A Medical Update. Indian J Pediatr 76, 77–81 (2009). https://doi.org/10.1007/s12098-009-0032-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-009-0032-2